Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Blood and Lymph Conditions

Nervous System Diseases

Rare Diseases

Recurrence

Esophageal Neoplasms

Carcinoma

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Stomach Neoplasms

Head and Neck Neoplasms

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Papilloma

Carcinoma, Basal Cell

Breast Neoplasms, Male

Granuloma

Carcinoma, Adenoid Cystic

Esthesioneuroblastoma, Olfactory

Papilloma, Inverted

Carcinoma, Mucoepidermoid

Mucoepidermoid Tumor

Breast Diseases

Skin Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Esophageal Diseases

Esophageal Cancer

Ovarian Cancer

Stomach Cancer

Ovarian Epithelial Cancer

Breast Cancer, Male

Germ Cells Tumors

Laryngeal Cancer

Hypopharyngeal Cancer

Ovarian Germ Cell Tumor

Adenoid Cystic Carcinoma

Olfactory Neuroblastoma

Mucoepidermoid Carcinoma

Midline Lethal Granuloma

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Docetaxel

Pemetrexed

Taxane

Folic Acid Antagonists

Tubulin Modulators

Antimitotic Agents

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folinic Acid

Folate

Vitamin B9

Alimta and Taxotere given in combination with dose modifications.

Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.

Taxotere (Docetaxel)

ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.

Alimta (Pemetrexed)

Lee Cranmer, MD, PhD

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of giving pemetrexed disodium and docetaxel together in treating patients with advanced solid tumors.

OBJECTIVES:

Primary

* To determine the maximum-tolerated dose of the combination of pemetrexed disodium and docetaxel when administered on a day 1 and day 15 dosing schedule.

Secondary

* To specifically characterize the toxicity profile for the combination of biweekly pemetrexed disodium and docetaxel.
* To investigate the antitumor activity in patients with advanced solid tumors as measured by RECIST criteria for patients with measurable disease or tumor markers for patients with non-measurable disease.
* To determine the recommended phase II dose of the combination of pemetrexed disodium and docetaxel on a biweekly dosing schedule.

OUTLINE: This is a dose-escalation study.

Patients receive pemetrexed disodium IV over 10 minutes and docetaxel IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients

National Cancer Institute (NCI)

University of Arizona

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors	NCT01172028	Breast Cancer Esophageal Canc... Gastric Cancer Head and Neck C... Lung Cancer Ovarian Cancer Prostate Cancer	Taxotere (Docet... Alimta (Pemetre...	18 Years -	University of Arizona
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors	NCT01172028	Breast Cancer Esophageal Canc... Gastric Cancer Head and Neck C... Lung Cancer Ovarian Cancer Prostate Cancer	Taxotere (Docet... Alimta (Pemetre...	18 Years -	University of Arizona

Spots Global Cancer Trial Database for alimta (pemetrexed)